Pluri Partners with ZEO ScientifiX to Expand U.S. Biologics
Pluri will acquire a 50% stake in the Davie-based firm to bolster manufacturing capacity for regenerative medicine.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you believe partnerships between biotech companies generally result in better medical treatment options?
Pluri and ZEO ScientifiX have signed a definitive strategic partnership agreement that includes Pluri taking a 50% ownership stake in the company. The deal combines Pluri's advanced cell technology with ZEO's established commercial and manufacturing infrastructure.
Why it matters
The partnership aims to expand U.S. manufacturing capabilities in the sectors of regenerative medicine and aesthetics. By integrating their operations, the companies hope to leverage their combined technological assets to increase market presence.
Pluri contributes proprietary manufacturing technology and know-how supported by a portfolio of over 200 patents. ZEO will issue common stock representing 50% of its total issued and outstanding shares to finalize the ownership transition.
The players
Pluri
An international biotechnology company based in Haifa, Israel, that focuses on cell technology and maintains a large patent portfolio.
ZEO ScientifiX
A biologics manufacturing company headquartered at Nova Southeastern University's Center for Collaborative Research in Davie, Florida.
The details
Under the agreement, ZEO will gain defined rights to utilize Pluri's core cell manufacturing technology. Pluri will retain full ownership of its underlying intellectual property throughout the duration of this strategic collaboration.
Timeline
October 26, 2026: The companies announced the definitive strategic partnership agreement.
Q4 2026: The transaction is expected to officially close.
The Tech Race
This deal underscores a broader push toward vertical integration within the field of regenerative medicine technology platforms. It positions the combined entity to better compete against established players by merging specialized cell technology with domestic manufacturing capacity.
For stakeholders and investors, this move marks a shift in how these biotechnology firms will scale their commercial output and manufacturing reach. The consolidation of these businesses aims to accelerate the availability of potential future treatments in aesthetics and medicine.
The takeaway
Strategic partnerships often allow mid-sized biotech firms to bridge the gap between proprietary research and large-scale commercial manufacturing. Investors should monitor how the integration of disparate intellectual property portfolios impacts future operational efficiency.
What happens next
The transaction is scheduled for completion in the fourth quarter of 2026, at which point ZEO's financial results will begin to be consolidated into Pluri's financial statements.
Further reading
Learn more about the latest innovations in the Biotech sector.
Live Poll
Do you believe partnerships between biotech companies generally result in better medical treatment options?
